Cited by 170Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Cohn, Jeffrey S., Patterson, Bruce W., Uffelman, Kris D., Davignon, Jean, Steiner, George·2004·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jc.2003-032056

Open this paper in CoChat — free account

Abstract

Overweight individuals with reduced insulin sensitivity often have mild to moderate hypertriglyceridemia. To investigate the role of apolipoprotein (apo)C-III metabolism in the etiology of hypertriglyceridemia in these individuals, we investigated 10 male subjects with different body weights (body mass index, 24-34 kg/m(2)) and insulin sensitivity (homeostasis model assessment, 4.7-35.0). Total plasma and very-low-density lipoprotein (VLDL) apoC-III kinetics, as well as VLDL triglyceride (TG) and VLDL apoB kinetics, were measured with iv injected stable isotopes. The apoC-III, TG, and apoB levels in VLDL ranged from 2.9-18.2 mg/dl, 0.49-2.89 mmol/liter, and 6.7-29.3 mg/dl, respectively. Mean production rates (PRs) were: VLDL apoC-III, 20.2 +/- 4.1 micromol/d (range, 8.0-44.8); VLDL TG, 26.9 +/- 4.6 mmol/d (range, 10.2-51.1); and VLDL apoB, 4.4 +/- 0.8 micromol/d (range, 1.5-9.1). VLDL apoC-III PRs were significantly correlated with body mass index, homeostasis model assessment, and plasma TG (r = 0.66, P < 0.05; r = 0.80, P < 0.01; r = 0.95, P < 0.001, respectively). Similar correlations were found for plasma apoC-III PRs (r = 0.70, P < 0.05; r = 0.67, P < 0.05; r = 0.80, P < 0.01, respectively). Fractional catabolic rates (FCRs) were not significantly related to metabolic variables. VLDL TG levels were strongly related to VLDL apoC-III levels (r = 0.99, P < 0.001) and VLDL apoC-III PRs (r = 0.94, P < 0.001). VLDL apoC-III levels were more strongly correlated with VLDL TG PRs (r = 0.81, P < 0.01) than with VLDL TG FCRs or VLDL apoB FCRs (r = -0.53, P = 0.12; r = -0.37, P = 0.29). These results suggest that increased hepatic production of VLDL apoC-III is characteristic of subjects with higher body weights and lower levels of insulin sensitivity and is strongly related to the plasma concentration and level of production of VLDL TG.

Integrity signals

Registry

Crossref · 10.1210/jc.2003-032056

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,372
Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes
Lewis, G. F., Carpentier, A. C., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,370
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Brown, W. V., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 493
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
Aalto‐Setälä, K., Fisher, E. A. A., Chen, X., Chajek‐Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 453
Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources
Havel, R. J., Fielding, C. J., Olivecrona, T., Shore, V. G., Fielding, P. E., & Egelrud, T. (1973) · Biochemistry · doi:10.1021/bi00733a026 · Cited by 332
Effects of Acute Hyperinsulinemia on VLDL Triglyceride and VLDL ApoB Production in Normal Weight and Obese Individuals
Lewis, G. F., Uffelman, K. D., Szeto, L., & Steiner, G. A. (1993) · Diabetes · doi:10.2337/diab.42.6.833 · Cited by 323
Self-citation
Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver.
Windler, E. E. T., & Havel, R. J. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34342-x · Cited by 314
Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia.
Maeda, N., Li, H., Lee, D., Oliver, P. M., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
Shachter, N. S. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00009 · Cited by 288
Transport of Very Low Density Lipoprotein Triglycerides in Varying Degrees of Obesity and Hypertriglyceridemia
Grundy, S. M., Mok, H. Y. I., Zech, L. A., Steinberg, D. H., & Berman, M. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109422 · Cited by 283
Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia.
Li, W. W., Dammerman, M. M., Smith, J. D., Metzger, S., Breslow, J. L., & Leff, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118324 · Cited by 278
An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms.
Dammerman, M., Sandkuijl, L. A., Halaas, J. L., Chung, W. K., & Breslow, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4562 · Cited by 226
Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E.
de Silva, H. V., Lauer, S. J., Wang, J., Simonet, W. S., Weisgraber, K. H., Mahley, R. W., & Taylor, J. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42171-5 · Cited by 215
Prevention Conference VI: Diabetes and Cardiovascular Disease
Eckel, R. H., Wassef, M. K., Chait, A., Sobel, B. E., Barrett, E. J., King, G. L., Lopes-Virella, M. F., Reusch, J. E. B., Ruderman, N. B., Steiner, G. A., et al. (2002) · Circulation · doi:10.1161/01.cir.0000013954.65303.c5 · Cited by 199
Self-citation
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
Ebara, T., Ramakrishnan, R., Steiner, G. A., & Shachter, N. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119456 · Cited by 195
Self-citation
Mechanisms of Hepatic Very Low-Density Lipoprotein Overproduction in Insulin Resistance
Adeli, K., Taghibiglou, C., Van Iderstine, S. C., & Lewis, G. F. (2001) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00084-6 · Cited by 194
Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.
Chen, M., Breslow, J. L., Li, W., & Leff, T. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39938-7 · Cited by 183
Apolipoprotein C-II and C-III levels in hyperlipoproteinemia
Schonfeld, G., George, P. K., Miller, J. P., Reilly, P., & Witztum, J. L. (1979) · Metabolism · doi:10.1016/0026-0495(79)90004-0 · Cited by 179
Modulation of Lipoprotein B Binding to the LDL Receptor by Exogenous Lipids and Apolipoproteins CI, CII, CIII, and E
Barthelemy-Clavey, V., Lestavel-Delattre, S., Copin, C., Bard, J., & Fruchart, J. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.7.963 · Cited by 178
Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism
Cobelli, C., TOFFOLO, G. M., & Foster, D. M. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.262.6.e968 · Cited by 177
Influence of obesity on the metabolism of apolipoprotein B in humans.
Egusa, G., Beltz, W. F., Grundy, S. M., & Howard, B. V. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112011 · Cited by 167
Quantitative determination of human apolipoprotein Cc-III by electroimmunoassay
Curry, M. D., McConathy, W. J., Fesmire, J. D., & Alaupovic, P. (1980) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(80)90016-8 · Cited by 140
Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease.
Kesäniemi, Y. A., Beltz, W. F., & Grundy, S. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112010 · Cited by 140
Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration
Chan, D. C., Watts, G. F., Redgrave, T. G., Mori, T. A., & Barrett, P. H. R. (2002) · Metabolism · doi:10.1053/meta.2002.33339 · Cited by 137
Effect of sex and obesity on basal VLDL-triacylglycerol kinetics
Mittendorfer, B., Patterson, B. W., & Klein, S. (2003) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.3.573 · Cited by 132
Self-citation
Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity
Riches, F. M., Watts, G. F., Naoumova, R. P., Kelly, J., Croft, K. D., & Thompson, G. (1998) · International Journal of Obesity · doi:10.1038/sj.ijo.0800602 · Cited by 126
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Haubenwallner, S., Essenburg, A. D., Barnett, B. C., Pape, M. E., Demattos, R. B., Krause, B. R., Minton, L. L., Auerbach, B. J., Newton, R. S., & Leff, T. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41090-9 · Cited by 118
Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions
Fredenrich, A., Giroux, L.-M., Tremblay, M., Krimbou, L., Davignon, J., & Cohn, J. S. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37424-1 · Cited by 115
Self-citation
Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
Aalto‐Setälä, K., Weinstock, P. H., Bisgaier, C. L., Wu, L., Smith, J. D., & Breslow, J. L. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39123-9 · Cited by 114
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113
Self-citation
Polymorphic Markers in Apolipoprotein C-III Gene Flanking Regions and Hypertriglyceridemia
Surguchov, A. P., Page, G. P., Smith, L. C., Patsch, W., & Boerwinkle, E. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.8.941 · Cited by 110
Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM
Taskinen, M., Packard, C. J., & Shepherd, J. (1990) · Diabetes · doi:10.2337/diab.39.9.1017 · Cited by 103
Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration
Malmendier, C. L., Lontie, J., Delcroix, C., Dubois, D. Y., Magot, T., & Roy, L. D. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90075-0 · Cited by 94
ApoCIII Gene Variants Modulate Postprandial Response to Both Glucose and Fat Tolerance Tests
Waterworth, D. M., Ribalta, J., Nicaud, V., Dallongeville, J., Humphries, S. E., & Talmud, P. J. (1999) · Circulation · doi:10.1161/01.cir.99.14.1872 · Cited by 86
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.
von Eckardstein, A., Holz, H., Sandkamp, M., Weng, W., Funke, H., & Assmann, G. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115190 · Cited by 81
Inhibitory Effects of Specific Apolipoprotein C-III Isoforms on the Binding of Triglyceride-rich Lipoproteins to the Lipolysis-stimulated Receptor
Mann, C. J., Troussard, A. A., Yen, F. T., Hannouche, N., Najïb, J., Fruchart, J., Lotteau, V., André, P., & Bihain, B. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31348 · Cited by 81
ApoC-III gene polymorphisms and risk of coronary artery disease
Olivieri, O., Stranieri, C., Bassi, A., Zaia, B., Girelli, D., Pizzolo, F., Trabetti, E., Cheng, S., Grow, M. A., Pignatti, P. F., et al. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200145-jlr200 · Cited by 70
Early Kinetic Abnormalities of ApoB-Containing Lipoproteins in Insulin-Resistant Women With Abdominal Obesity
Pont, F., Duvillard, L., Florentin, E., Gambert, P., & Vergès, B. L. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000032134.92180.41 · Cited by 63
Familial HDL Deficiency Characterized by Hypercatabolism of Mature ApoA-I but Not ProApoA-I
Batal, R., Tremblay, M., Krimbou, L., Mamer, O., Davignon, J., Genest, J. J., & Cohn, J. S. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.4.655 · Cited by 61
Self-citation
Improved method for quantitation of B apoprotein in plasma lipoproteins by electroimmunoassay.
Reardon, M., Poapst, M. E., Uffelman, K. D., & Steiner, G. A. (1981) · Clinical Chemistry · doi:10.1093/clinchem/27.6.892 · Cited by 58
Self-citation
Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis.
Forte, T. M., Nichols, A. V., Krauss, R. M., & Norum, R. A. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111576 · Cited by 57
Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease.
Lee, S.-J., Moye, L. A., Campos, H., Williams, G. H., & Sacks, F. M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00007-8 · Cited by 50
Modulation of lipoprotein production in hep G2 cells by fenofibrate and clofibrate
Hahn, S. E., & Goldberg, D. M. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90586-8 · Cited by 49
Effect of obesity on the relationship between very low density lipoprotein production rate and plasma triglyceride concentration in normal and hypertriglyceridemic subjects
Reaven, G. M., & Bernstein, R. M. (1978) · Metabolism · doi:10.1016/0026-0495(78)90150-6 · Cited by 49
A stable isotope method using a [2H5]glycerol bolus to measure very low density lipoprotein triglyceride kinetics in humans
Lemieux, S., Patterson, B. W., Carpentier, A. C., Lewis, G. F., & Steiner, G. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32434-2 · Cited by 45
Self-citation
Very low density lipoprotein metabolism in diabetes mellitus
Ginsberg, H. N. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030209 · Cited by 43
A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia
Ribalta, J., Ville, A. E. L., Vallvé, J.-C., Humphries, S. E., Turner, P. R., & Masana, L. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37189-3 · Cited by 42
Sensitivity to Acute Insulin-Mediated Suppression of Plasma Free Fatty Acids Is Not a Determinant of Fasting VLDL Triglyceride Secretion in Healthy Humans
Carpentier, A. C., Patterson, B. W., Leung, N. M., & Lewis, G. F. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1867 · Cited by 41
Self-citation
Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C
van Barlingen, H. H. J. J., de Jong, H., Erkelens, D. W., & de Bruin, T. W. A. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37573-8 · Cited by 40
Interactions Between Glucose and FFA Metabolism in Man
Saloranta, C., & Groop, L. (1996) · Diabetes/Metabolism Reviews · doi:10.1002/(sici)1099-0895(199603)12:1 · Cited by 37
Self-citation
Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men
Waterworth, D. M., Talmud, P. J., Luan, J., Flavell, D. M., Byrne, C. D., Humphries, S. E., & Wareham, N. J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(03)00021-8 · Cited by 37
[5] Apolipoprotein B-48
Karpe, F., Hamsten, A., Uffelman, K. D., & Steiner, G. A. (1996) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(96)63007-9 · Cited by 35
Self-citation
Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase
Landis, B. A., Rotolo, F. S., Meyers, W. C., Clark, A. B., & Quarfordt, S. H. (1987) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1987.252.6.g805 · Cited by 32
Hyperinsulinemia and VLDL Kinetics
Steiner, G. A. (1993) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2910-1_22 · Cited by 4
Self-citation
Level of apoC-III mRNA correlates positively to the secretion of triglyceride-rich VLDL from transfected McA-RH7777 cells
Rahimkhani, S., Tran, K. T., Wang, Y., & Yao, Z. (2000) · Cited by 3

Flagged first, then by citations

Sorted by citations

Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
“The increase in triglyceride production may be due to excess free fatty acids returning to the liver, particularly in the setting of visceral obesity and insulin resistance, and increased de novo triglyceride production due to hyperinsulinemia (24, 62, 63).”
Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes
Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Choi, S. H., & Ginsberg, H. N. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.007 · Cited by 418
Fat Depots, Free Fatty Acids, and Dyslipidemia
Ebbert, J. O., & Jensen, M. D. (2013) · Nutrients · doi:10.3390/nu5020498 · Cited by 355

See all 170

Authors: Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G.
Affiliations: Montreal Clinical Research Institute (CA)
Washington University in St. Louis (US)
Toronto General Hospital (CA)
Corresponding author: Cohn, Jeffrey S.
ORCID: Cohn, Jeffrey S.
Patterson, Bruce W.
Davignon, Jean
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 2004-08
Volume: 89
Issue: 8
Pages: 3949-3955
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jc.2003-032056
OpenAlex: W1994130325
Cited by: 170
References: 58
Citations by year: 2026: 4 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 12 · 2019: 10 · 2018: 5 · 2017: 7 · 2016: 9 · 2015: 10 · 2014: 8 · 2013: 15 · 2012: 9
FWCI: 5.01
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: apolipoprotein C-III, VLDL triglycerides, hypertriglyceridemia, insulin sensitivity, overweight, body mass index, fractional catabolic rate
MeSH terms: Adult, Apolipoproteins C, Body Weight, Humans, Insulin, Insulin Resistance, Kinetics, Lipoproteins, VLDL, Male, Middle Aged, Osmolar Concentration, Triglycerides, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks